Kalaris Therapeutics, Inc.
KLRS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001754068
No open-market purchases or sales by Kalaris Therapeutics, Inc. insiders were filed in the last 90 days; 56 institutions reported holding it in 13F filings for Q2 2026, worth $73.4M in total; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding Kalaris Therapeutics, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 72 | 1 | 60 | −11 |
| Shares | 46.8M | 634.0K | 44.9M | −1.32M (−2.9%) |
| Value | $33.9M | $458.6K | $36.3M | +$2.87M (+8.6%) |
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (3)
Institutions that held Kalaris Therapeutics, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Siren, L.L.C. | 6,597,167 | $5.33M | 0.27% |
| BlackRock, Inc. | 632,890 | $511.7K | 0.00% |
| Amundi | 45,448 | $36.0K | 0.00% |
Sold out (14)
Institutions that held Kalaris Therapeutics, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Artal Group S.A. | 6,597,167 | $4.77M |
| Pennant Investors, LP | 215,700 | $156.0K |
| Y-Intercept (Hong Kong) Ltd | 194,473 | $140.7K |
| Centiva Capital, LP | 137,897 | $99.7K |
| Gsa Capital Partners LLP | 51,224 | $37.0K |
| Paloma Partners Management Co | 31,765 | $23.0K |
| Mirae Asset Global ETFs Holdings Ltd. | 26,032 | $18.8K |
| Rhumbline Advisers | 18,494 | $13.4K |
| Balyasny Asset Management LLC | 15,947 | $11.5K |
| Jump Financial, LLC | 14,565 | $10.5K |
| Royal Bank of Canada | 9,294 | $7.00K |
| Macquarie Group Ltd | 2,561 | $1.85K |
| New York State Common Retirement Fund | 467 | $338 |
| Avion Wealth | 683 | $0 |
Not filed for Q3 2024 yet (1)
Institutions that held Kalaris Therapeutics, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 634,020 | $458.6K |